Guard Therapeutics: New strengthening data from AKITA study - Redeye
Bildkälla: Stockfoto

Guard Therapeutics: New strengthening data from AKITA study - Redeye

Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its completed phase IIa study AKITA, which investigated RMC-035 as a renal protective agent during open-heart surgery. Furthermore, the company announced that topline results from the phase IIb study POINTER are anticipated in early November.

Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its completed phase IIa study AKITA, which investigated RMC-035 as a renal protective agent during open-heart surgery. Furthermore, the company announced that topline results from the phase IIb study POINTER are anticipated in early November.
Börsvärldens nyhetsbrev